the firm's post-grant practitioners are some of the most experienced in the country.

Technologies

Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our

History

Get to know our History

1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our

ACCOLADES

A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.

OPPORTUNITIES FOR YOUR

Career

OPPORTUNITIES FOR YOUR Career

From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +


Tokyo Office

Telephone: +81-3-6212-0550
Learn More +

Downloadable

Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

Stay informed with

Our Blogs

Patent Term Adjustment - A Dollar Won is Twice as Sweet as a Dollar Earned

Schedule :

Associated People


In this webinar we discussed the important topic of patent term adjustment (PTA) under 35 U.S.C. §154(b). Led primarily by the pharmaceutical industry where every day could mean millions of dollars, the USPTO regulations for calculating PTA have been under assault.  From Wyeth v. Kappos, 591 F.3d 1364, 93 USPQ2d (Fed. Cir. 2010) to Chudik v. Hirshfeld, 987 F.3d 1033, 1039 (Fed. Cir. 2021), the Court of Appeal for the Federal Circuit (CAFC) has been asked to review and has frequently found the USPTO’s regulations to be incorrect.   In this webinar we will discuss the current state of PTA, pitfalls applicants frequently fall into, and provide practical prosecution advice.  We also cover the interplay between PTA and obvious-type double patenting following Mitsubishi Tanabe Pharma Corp. v. Sandoz, Inc., 3:17-cv-05319-FLW-DEA, 2021 (D.N.J. Mar. 22, 2021).

This webinar was led by Vincent Shier and Richard Kelly.